Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000651254 | SCV000773105 | benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003311632 | SCV001500411 | likely benign | not provided | 2023-06-01 | criteria provided, single submitter | clinical testing | CACNA1S: BP4, BP7 |
Fulgent Genetics, |
RCV002507123 | SCV002807751 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5; Thyrotoxic periodic paralysis, susceptibility to, 1 | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003451572 | SCV004177846 | benign | Malignant hyperthermia, susceptibility to, 5 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003451573 | SCV004177848 | benign | Thyrotoxic periodic paralysis, susceptibility to, 1 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003458493 | SCV004177849 | benign | Congenital myopathy 18 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003456119 | SCV004177850 | benign | Hypokalemic periodic paralysis, type 1 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003451572 | SCV004823500 | benign | Malignant hyperthermia, susceptibility to, 5 | 2024-02-05 | criteria provided, single submitter | clinical testing |